<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Toxics</journal-id><journal-id journal-id-type="iso-abbrev">Toxics</journal-id><journal-id journal-id-type="publisher-id">toxics</journal-id><journal-title-group><journal-title>Toxics</journal-title></journal-title-group><issn pub-type="epub">2305-6304</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">39997888</article-id><article-id pub-id-type="pmc">PMC11860425</article-id>
<article-id pub-id-type="doi">10.3390/toxics13020070</article-id><article-id pub-id-type="publisher-id">toxics-13-00070</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Evaluating the Risks of Heated Tobacco Products: Toxicological Effects on Two Selected Respiratory Bacteria and Human Lung Cells</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0009-0001-4553-743X</contrib-id><name><surname>Furnari</surname><given-names>Salvatore</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x02013; original draft</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><xref rid="af1-toxics-13-00070" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Emma</surname><given-names>Rosalia</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><xref rid="af2-toxics-13-00070" ref-type="aff">2</xref><xref rid="af3-toxics-13-00070" ref-type="aff">3</xref><xref rid="c1-toxics-13-00070" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-4412-2080</contrib-id><name><surname>Caruso</surname><given-names>Massimo</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><xref rid="af1-toxics-13-00070" ref-type="aff">1</xref><xref rid="af2-toxics-13-00070" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-1782-9758</contrib-id><name><surname>Furneri</surname><given-names>Pio Maria</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><xref rid="af1-toxics-13-00070" ref-type="aff">1</xref><xref rid="af2-toxics-13-00070" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-0405-5095</contrib-id><name><surname>Fuochi</surname><given-names>Virginia</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x02013; original draft</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><xref rid="af1-toxics-13-00070" ref-type="aff">1</xref><xref rid="af2-toxics-13-00070" ref-type="aff">2</xref><xref rid="c1-toxics-13-00070" ref-type="corresp">*</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name><surname>Larcombe</surname><given-names>Alexander N.</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-toxics-13-00070"><label>1</label>Department of Biomedical and Biotechnological Sciences (BIOMETEC), University of Catania, 95124 Catania, Italy<email>massimo.caruso@unict.it</email> (M.C.); <email>furneri@unict.it</email> (P.M.F.)</aff><aff id="af2-toxics-13-00070"><label>2</label>Center of Excellence for the Acceleration of Harm Reduction (CoEHAR), University of Catania, 95124 Catania, Italy</aff><aff id="af3-toxics-13-00070"><label>3</label>Department of Clinical and Experimental Medicine (MEDCLIN), University of Catania, 95124 Catania, Italy</aff><author-notes><corresp id="c1-toxics-13-00070"><label>*</label>Correspondence: <email>rosalia.emma@unict.it</email> (R.E.); <email>virginia.fuochi@unict.it</email> (V.F.)</corresp></author-notes><pub-date pub-type="epub"><day>21</day><month>1</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>2</month><year>2025</year></pub-date><volume>13</volume><issue>2</issue><elocation-id>70</elocation-id><history><date date-type="received"><day>12</day><month>12</month><year>2024</year></date><date date-type="rev-recd"><day>16</day><month>1</month><year>2025</year></date><date date-type="accepted"><day>20</day><month>1</month><year>2025</year></date></history><permissions><copyright-statement>&#x000a9; 2025 by the authors.</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p>Heated tobacco products (THPs) are increasingly promoted as potential harm reduction tools, offering an alternative to traditional cigarettes. Despite these claims, understanding of their toxicological impact on respiratory health and associated microbial communities is limited. Comprehensive investigations are needed to elucidate the biological mechanisms and potential health implications associated with their use. Methods: This study evaluated the toxicological effects of aerosols produced by THPs (IQOS 3 Duo with Heets &#x0201c;Sienna Selection&#x0201d;) in comparison to conventional cigarette smoke (1R6F). Antibacterial activity was evaluated using <italic toggle="yes">Streptococcus pneumoniae</italic> and <italic toggle="yes">Klebsiella pneumoniae</italic> as representative species of the respiratory microbiota through agar diffusion assays and MIC/MBC determinations. Cytotoxicity was assessed in human lung fibroblast cells (MRC5) through the neutral red uptake (NRU) assay, whereas mutagenicity was investigated using the Ames test. Results: THP aerosols demonstrated the ability to inhibit the growth of both <italic toggle="yes">S. pneumoniae</italic> and <italic toggle="yes">K. pneumoniae</italic>, exerting bacteriostatic effects at lower concentrations and bactericidal effects at higher concentrations. While these antibacterial effects might initially seem beneficial against pathogens such as <italic toggle="yes">K. pneumoniae</italic>, they raise concerns about the potential disruption of the respiratory microbial balance, particularly in relation to <italic toggle="yes">S. pneumoniae</italic>. Despite these microbiological effects, THP aerosols demonstrated minimal cytotoxicity on human lung fibroblasts and lacked detectable mutagenic activity, contrasting with the significant cytotoxicity and mutagenicity caused by cigarette smoke. Conclusions: THPs present a reduced short-term toxicological profile compared with conventional cigarettes; however, their effects on respiratory microorganisms deserve attention. The observed inhibition of commensal bacteria highlights the need to explore potential changes in the microbial ecosystem that could affect respiratory health. These findings highlight the need for additional studies to evaluate the long-term effect of THP use on respiratory microbiota and the stability of the overall microbial ecosystem.</p></abstract><kwd-group><kwd>tobacco heating products (THPs)</kwd><kwd><italic toggle="yes">Streptococcus pneumoniae</italic></kwd><kwd><italic toggle="yes">Klebsiella pneumoniae</italic></kwd><kwd>lung health</kwd><kwd>respiratory microbial communities</kwd><kwd>cytotoxicity</kwd><kwd>mutagenicity</kwd></kwd-group><funding-group><funding-statement>This research received no external funding.</funding-statement></funding-group></article-meta></front><body><sec sec-type="intro" id="sec1-toxics-13-00070"><title>1. Introduction</title><p>Over the past few years, the spreading of heated tobacco products (THPs) has set off significant debate in public health, as these devices are frequently reported as a potentially safer alternative to traditional cigarettes [<xref rid="B1-toxics-13-00070" ref-type="bibr">1</xref>,<xref rid="B2-toxics-13-00070" ref-type="bibr">2</xref>,<xref rid="B3-toxics-13-00070" ref-type="bibr">3</xref>]. Unlike traditional cigarettes, THPs heat tobacco without triggering combustion, thereby minimizing the production of many harmful and potentially harmful substances, including tar and carbon monoxide [<xref rid="B4-toxics-13-00070" ref-type="bibr">4</xref>,<xref rid="B5-toxics-13-00070" ref-type="bibr">5</xref>]. This has led to the suggestion that THPs may pose fewer risks to human health, particularly in relation to respiratory and cardiovascular diseases [<xref rid="B6-toxics-13-00070" ref-type="bibr">6</xref>,<xref rid="B7-toxics-13-00070" ref-type="bibr">7</xref>]. However, the reduced-risk claim is not unequivocally supported by evidence, as the long-term biological and public health impacts of THPs remain poorly understood [<xref rid="B8-toxics-13-00070" ref-type="bibr">8</xref>].</p><p>Among the advantages of using THPs instead of classic cigarettes is the fact that THP companies highlight the potential of THPs to reduce exposure to toxicants, and additionally, they are often marketed as tools for harm reduction, targeting smokers unable or unwilling to quite nicotine use entirely [<xref rid="B9-toxics-13-00070" ref-type="bibr">9</xref>]. Despite this, critics argue that THPs are far from risk-free [<xref rid="B10-toxics-13-00070" ref-type="bibr">10</xref>]. Actually, many research suggest that these products can still deliver nicotine and other harmful substances at levels capable of inducing adverse effects, including oxidative stress, inflammation, and impaired immune response [<xref rid="B11-toxics-13-00070" ref-type="bibr">11</xref>]. Moreover, the aerosol produced by THPs may include unique toxicological profiles distinct from traditional cigarette smoke, with unknown implications for lung health and systemic diseases [<xref rid="B12-toxics-13-00070" ref-type="bibr">12</xref>].</p><p>Recent research has shifted focus from the chemical analysis of THPs to exploring their biological effects, particularly their interactions with microbial communities. A notable area of investigation is the influence of THP aerosols on bacteria, which are integral to the microbial ecology of environments such as the human respiratory tract. This line of inquiry is important for several reasons. The respiratory tract contains a diverse array of bacteria that contribute to physiological functions and help maintain microbial balance [<xref rid="B13-toxics-13-00070" ref-type="bibr">13</xref>]. Disruptions to this balance have been associated with various respiratory conditions, highlighting the need to study how THPs may affect these communities [<xref rid="B14-toxics-13-00070" ref-type="bibr">14</xref>,<xref rid="B15-toxics-13-00070" ref-type="bibr">15</xref>]. Evaluating the effects of THP aerosols on both pathogenic and commensal microbiota could provide valuable insights into their broader impact on respiratory health [<xref rid="B16-toxics-13-00070" ref-type="bibr">16</xref>].</p><p>One of the key components of the resident microbiota is <italic toggle="yes">Streptococcus pneumoniae</italic>, a common commensal of the nasopharynx in healthy individuals that plays a significant role in the respiratory microbiota [<xref rid="B17-toxics-13-00070" ref-type="bibr">17</xref>,<xref rid="B18-toxics-13-00070" ref-type="bibr">18</xref>]. However, under dysbiotic conditions, <italic toggle="yes">S. pneumoniae</italic> can transition from a benign resident to a pathogen, capable of causing invasive diseases such as pneumonia, sepsis, and meningitis [<xref rid="B19-toxics-13-00070" ref-type="bibr">19</xref>,<xref rid="B20-toxics-13-00070" ref-type="bibr">20</xref>]. Similarly, <italic toggle="yes">Klebsiella pneumoniae</italic>, another opportunistic pathogen, is part of the normal microbiota of the upper respiratory tract and gastrointestinal system but can become a major cause of hospital- and community-acquired infections, including pneumonia and bloodstream infections, particularly under conditions of microbial imbalance [<xref rid="B21-toxics-13-00070" ref-type="bibr">21</xref>,<xref rid="B22-toxics-13-00070" ref-type="bibr">22</xref>,<xref rid="B23-toxics-13-00070" ref-type="bibr">23</xref>]. Smoking has been identified as a major risk factor for diseases associated with both <italic toggle="yes">S. pneumoniae</italic> and <italic toggle="yes">K. pneumoniae</italic>, largely due to its ability to impair mucociliary clearance, modulate immune responses, and enhance bacterial adherence to epithelial cells [<xref rid="B24-toxics-13-00070" ref-type="bibr">24</xref>]. Cigarette smoke, for example, alters the microbial landscape of the nasopharynx and lower airways, creating conditions favorable for the colonization and overgrowth of opportunistic pathogens such as <italic toggle="yes">S. pneumoniae</italic> and <italic toggle="yes">K. pneumoniae</italic> [<xref rid="B25-toxics-13-00070" ref-type="bibr">25</xref>]. While THPs emit aerosols with a different toxicological profile, their impact on the respiratory microbiota and potential to promote similar pathogenic transitions remains an open question. In the context of THP use, the extent to which these products contribute to dysbiosis and enhance the pathogenic potential of bacteria such as <italic toggle="yes">S. pneumoniae</italic> and <italic toggle="yes">K. pneumoniae</italic> remains underexplored. Investigating these interactions is crucial to understanding whether THPs truly represent a safer alternative to conventional cigarettes or pose distinct risks to respiratory health [<xref rid="B26-toxics-13-00070" ref-type="bibr">26</xref>]. Explorations into these dynamics are essential for shaping evidence-based regulatory policies and public health recommendations regarding THP use.</p><p>The main objective of this study was to investigate the biological effects of aerosols generated by THPs, with a particular focus on their effects on the proliferation of two bacterial models&#x02014;one Gram-positive and one Gram-negative&#x02014;driven by their respective roles as major agents of bacterial pneumonia. Specifically, we aimed to determine whether the proliferation of <italic toggle="yes">S. pneumoniae</italic> and <italic toggle="yes">K. pneumoniae</italic> is altered in the presence of THP aerosols, as this could indicate potential impacts on respiratory health and inflammation compared to traditional cigarettes.</p><p>To address these questions, we utilized a combination of quantitative and qualitative assays to specifically evaluate the cytotoxicity, mutagenicity and antimicrobial effects of aerosols generated by the IQOS 3 Duo device with Heets &#x0201c;Sienna Selection&#x0201d; in comparison to the biological activity of traditional tobacco smoke produced by 1R6F Kentucky reference cigarettes. Additionally, an Ames test was conducted to evaluate the mutagenic potential of the aerosol, providing insights into genotoxic risks. Human lung fibroblast diploid cells (MRC-5) were also exposed to cigarette smoke and IQOS vapors to investigate cytotoxic effects on lung tissue. These experiments were designed to offer a thorough evaluation of the relative safety of THPs, focusing on their effects on microbial communities and cellular responses.</p></sec><sec id="sec2-toxics-13-00070"><title>2. Materials and Methods</title><sec id="sec2dot1-toxics-13-00070"><title>2.1. Bacterial Strain</title><p><italic toggle="yes">Streptococcus pneumoniae</italic> ATCC 49619 and <italic toggle="yes">Klebsiella pneumoniae</italic> ATCC 700603 strains were used for our purpose (collection of the Laboratory of Applied Microbiology, Department of Biomedical and Biotechnological Sciences, Universit&#x000e0; di Catania).</p></sec><sec id="sec2dot2-toxics-13-00070"><title>2.2. Smoke and Aerosol Generation and Aqueous Extracts (AqExs) Production</title><p>AqExs were generated by bubbling whole cigarette smoke or THP vapors through 40 mL of CAMHB medium (Cationic Adjusted Mueller Hinton Broth; Oxoid, UK) using a glass impinger trap. 1R6F reference cigarettes (Center for Tobacco Reference Products, University of Kentucky) were smoked using the LM1 smoking machine (Borgwaldt KC GmbH, Hamburg, Germany), while the THPs were vaped using the LM4E vaping machine (Borgwaldt KC GmbH, Hamburg, Germany). The IQOS 3 Duo (Philip Morris Products SA, Lausanne, Switzerland) equipped with Heets &#x0201c;Sienna Selection&#x0201d; was vaped following the Health Canada Intense (HCI) regimen (55 mL puff volume, 3 s puff duration, 30 s inter-puff interval, bell-shaped profile) without blocking the ventilation holes, for a total of 120 puffs (10 Heets &#x000d7; 12 puffs). Moreover, six 1R6F tobacco reference cigarettes (University of Kentucky) were smoked following the HCI regimen (55 mL puff volume, 3 s puff duration, 30 s inter-puff interval, bell-shaped profile) with blocked ventilation holes, for a total of 48 puffs (6 cigarettes &#x000d7; 8 puffs). The aliquots of bubbled media were filtered through a 0.22 &#x000b5;m filter (Millex<sup>&#x000ae;</sup> Filter Units with MF-Millipore&#x02122; Membrane, Sigma-Aldrich, Merck, Darmstadt, Germany) before carrying out subsequent assays to eliminate any contamination introduced during the bubbling process. Furthermore, pH measurements were taken both before and after exposure to smoke/vapors using a pH meter (Eutech pH 700, Eutech Instruments, ThermoFisher, Milan, Italy), which had been previously standardized at room temperature (23 &#x000b0;C). As part of the control procedure, the pH of sterile distilled water was also measured.</p></sec><sec id="sec2dot3-toxics-13-00070"><title>2.3. Agar Diffusion Test</title><p>The antibacterial activity of pure AqExs was assessed using the agar diffusion test, following the method described previously [<xref rid="B27-toxics-13-00070" ref-type="bibr">27</xref>,<xref rid="B28-toxics-13-00070" ref-type="bibr">28</xref>]. In brief, 100 &#x000b5;L of each sample was dispensed into blank discs in pre-inoculated plates (1.5 &#x000d7; 10<sup>5</sup> CFU mL<sup>&#x02212;1</sup>) of Antibiotic Agar Medium No.1 (AAM1; Sigma-Aldrich-Merck KGaA, Darmstadt, Germany), with 5% sheep blood for <italic toggle="yes">Streptococcus</italic>. Phosphate-Buffer Solution (PBS, 100 &#x000b5;L) served as negative control, while Ceftriaxone 30 &#x000b5;g (CRO) was used as positive control. Plates were incubated overnight at 37 &#x000b0;C under aerobic conditions for <italic toggle="yes">Klebsiella</italic> and in a 5% CO<sub>2</sub> atmosphere for <italic toggle="yes">Streptococcus</italic>. The inhibition zone diameters were measured in millimeters using a caliper, with a precision of 0.1 mm. Each determination was performed in triplicate within the same experiment, and the experiment was repeated three times. Results were expressed as mean &#x000b1; SD.</p></sec><sec id="sec2dot4-toxics-13-00070"><title>2.4. Minimum Inhibitory Concentration (MIC) and Minimum Bactericidal Concentration (MBC)</title><p>The assays were performed using 96-well polystyrene plates (Corning<sup>&#x000ae;</sup> 96 Well Microplates, Leipzig, Germany) with the two CAMHB AqExs:<list list-type="bullet"><list-item><p>CAMHB bubbled with tobacco cigarette smoke;</p></list-item><list-item><p>CAMHB bubbled with IQOS vapors.</p></list-item></list></p><p>According to the CLSI M100 guidelines, MIC values were determined using the microdilution method [<xref rid="B28-toxics-13-00070" ref-type="bibr">28</xref>]. The <italic toggle="yes">inocula</italic> were prepared from bacterial suspensions at a 0.5 McFarland standard, and dilutions in untreated broth were made to obtain final concentrations of 10<sup>4</sup>&#x02013;10<sup>5</sup> CFU mL<sup>&#x02212;1</sup>. The plates were incubated overnight at 37 &#x000b0;C under aerobic conditions. The tested concentration range of the bubbled media was from 100% to 6.25% <italic toggle="yes">v</italic>/<italic toggle="yes">v</italic>.</p><p>A negative control was performed using CAMHB bubbled with air only, ensuring no antibacterial activity from the medium itself.</p><p>The following day, MBC assays were conducted. A total of 10 &#x000b5;L of the dilutions corresponding to the MIC values, along with two more concentrated dilutions, was plated on AAM1 plates (with 5% of sheep blood for Streptococcus). After overnight incubation at 37 &#x000b0;C, the plates were examined, and viable CFU mL<sup>&#x02212;1</sup> was enumerated to determine the bactericidal activity.</p><p>Each determination was performed in six replicates within the same experiment, and the experiment was repeated six times. Results were expressed as the mode obtained above 50%.</p></sec><sec id="sec2dot5-toxics-13-00070"><title>2.5. Cell Cultures</title><p>The MRC-5 cell line (Lung Normal Fibroblast Cells, ATCC<sup>&#x000ae;</sup> CCL-171&#x02122;) was used for this study. The cells were cultured in DMEM HG medium (1-26F03-I BioConcept Ltd., Allschwil, Switzerland) supplemented with 10% fetal bovine serum (FBS), 2 mM L-Glutamine, and Penicillin-Streptomycin (10,000 IU/mL penicillin, 10 mg/mL streptomycin; 4-01F00-H BioConcept Ltd., Allschwil, Switzerland). Cell cultures were maintained at 37 &#x000b0;C in a humified environment with 95% air and 5% CO<sub>2</sub>.</p></sec><sec id="sec2dot6-toxics-13-00070"><title>2.6. Cell Viability Assay</title><p>To assess the cytotoxic effects of THPs vapors and 1R6F smoke on eukaryotic cells, the NRU assay was performed on MRC-5 cells following a precedent described [<xref rid="B29-toxics-13-00070" ref-type="bibr">29</xref>]. A suspension of MRC-5 cells (300 &#x003bc;L) was seeded into 24-well Transwell inserts at a density of 1.5 &#x000d7; 10<sup>5</sup> cells per well and incubated overnight. Following incubation, the apical medium was removed, and the inserts were relocated to exposure chambers containing 25 mL of DMEM HG to facilitate smoke/vapor ALI exposure. After the exposure, each insert was transferred to a new 24-well plate containing 500 &#x003bc;L of fresh medium in the basal compartment and 300 &#x003bc;L in the apical compartment, allowing the cells to recover for 65 &#x000b1; 2 h. One day prior to the NRU assay, NRU solution (0.05 g/L) was prepared in fresh medium (1:65) containing 20 mM HEPES buffer and incubated at 37 &#x000b0;C in a 5% CO<sub>2</sub> atmosphere. On the assay day, the solution was filtered, and the culture medium was removed from both compartments of the inserts. The cells were rinsed twice with pre-warmed PBS and then incubated with 500 &#x003bc;L of the NRU solution in the basal compartment and 300 &#x003bc;L in the apical compartment for 3 h at 37 &#x000b0;C in a humidified atmosphere containing 5% CO<sub>2</sub>. After incubation, unincorporated dye was removed by washing with PBS, and the dye retained within the cells was extracted by adding 330 &#x003bc;L of destain solution (50% ethanol, 49% distilled water, 1% glacial acetic acid) to each insert, followed by shaking at 300 rpm for 10 min. The extracts were transferred to a 96-well plate, with 100 &#x003bc;L added to each well, and the optical density was measured at 540 nm using a reference filter at 630 nm. Blank inserts (without cells) were included to account for background staining, and their values were subtracted from each measurement. The color intensity was determined using a Gen5 Microplate Reader (BioTek Instruments, Winooski, VT, USA). Each sample was analyzed in six replicates, and the results were reported as mean &#x000b1; SD.</p></sec><sec id="sec2dot7-toxics-13-00070"><title>2.7. Mutagenicity: AMES Screen</title><p>The in vitro mutagenicity of fresh 1R6F smoke and IQOS vapors was evaluated using the Ames test with <italic toggle="yes">Salmonella typhimurium</italic> strain TA98 (Trinova Biochem GmbH, Gie&#x000df;en, Germany) conducted with and without S9 metabolic activation, in accordance with OECD (Organisation for Economic Co-operation and Development) test guideline 471. Daunomycin (6.0 &#x000b5;g/plate) and 2-Aminoanthracene (10.0 &#x000b5;g/plate) were utilized as positive controls for the S9&#x02212; and S9+ treatments, respectively (ControlChem, Burlington, ON, Canada). Phosphate-buffered saline (PBS) and the S9+ mix served as solvent controls for the S9&#x02212; and S9+ treatments, respectively. Each concentration of the test vapor or smoke, as well as the positive controls, was tested in triplicate. To prepare the bacterial culture, one STDisc&#x02122; (Trinova Biochem GmbH, Gie&#x000df;en, Germania) was inoculated into 25 mL of Nutrient Broth No. 2 (OXOID) in a 50 mL falcon tube and incubated overnight at 37 &#x000b0;C with shaking at 120 rpm. The bacterial suspension was centrifuged at 1800&#x000d7; <italic toggle="yes">g</italic> for 20 min at 4 &#x000b0;C, and the resulting pellet was resuspended in 11 mL of Ca<sup>2+</sup>/Mg<sup>2+</sup>-free PBS. The bacterial suspensions were then exposed to the test aerosol at room temperature, while being shielded from direct light. Specifically, 10 mL of PBS bacterial suspension was placed in an impinger and bubbled with freshly generated smoke (1&#x02013;5 cigarettes) or aerosol (up to 30 puffs) from the LM1 smoking machine and LM4E vaping machine, respectively. Following each exposure, aliquots of the bacterial suspension were taken from the impingers and directly used for the Ames test, as outlined schematically in <xref rid="toxics-13-00070-t001" ref-type="table">Table 1</xref>. The suspension was thoroughly mixed and layered onto the top agar on the plates. Plates were rotated and tilted to ensure an even distribution of the top agar layer. Once the agar solidified, the plates were inverted and incubated at 37 &#x000b0;C. After 48 h of incubation, the number of revertant colonies on each plate was counted.</p></sec><sec id="sec2dot8-toxics-13-00070"><title>2.8. Statistical Analysis</title><p>Where applicable, data distribution was assessed using the Shapiro&#x02013;Wilk test; homoscedasticity was verified using the Brown&#x02013;Forsythe test. After the normality of the data was assessed, data were analyzed using one-way ANOVA with Bonferroni correction for multiple comparisons. For the agar diffusion test data, Kruskal&#x02013;Wallis test followed by Dunn&#x02019;s post hoc test was applied as the homoscedasticity assumption is not satisfied. The significance level was set at 5% (&#x003b1; = 0.05) for all statistical tests. All results and graphs were generated using GraphPad<sup>&#x000ae;</sup> Prism version 8.2.3 software.</p></sec></sec><sec sec-type="results" id="sec3-toxics-13-00070"><title>3. Results</title><sec id="sec3dot1-toxics-13-00070"><title>3.1. Antibacterial Activity</title><sec id="sec3dot1dot1-toxics-13-00070"><title>3.1.1. Comparative Efficacy of AqExs in Agar Diffusion Test</title><p>The agar diffusion assay demonstrated significant different antimicrobial effects across the tested solutions, as reported in <xref rid="toxics-13-00070-t002" ref-type="table">Table 2</xref> and illustrated in <xref rid="toxics-13-00070-f001" ref-type="fig">Figure 1</xref>. <italic toggle="yes">Streptococcus pneumoniae</italic> showed varying levels of susceptibility to the different AqExs. The IQOS AqEx exhibited an antibacterial effect, with an inhibition zone of 22 &#x000b1; 0.2 mm, while the 1R6F cigarette smoke AqEx produced the largest inhibition zone, measuring 29 &#x000b1; 0.2 mm. Similarly, <italic toggle="yes">Klebsiella pneumoniae</italic> demonstrated susceptibility, with inhibition zones of 21 &#x000b1; 0.1 mm for IQOS AqEx and 27 &#x000b1; 0.3 mm for 1R6F cigarette smoke AqEx. For comparison, phosphate-buffered saline (PBS), used as a negative control, did not exhibit any inhibition (&#x02264;6 mm), whereas the positive control, Ceftriaxone (CRO 30 &#x000b5;g), showed inhibition zones of 26 &#x000b1; 0.1 mm for <italic toggle="yes">S. pneumoniae</italic> and 23 &#x000b1; 0.2 mm for <italic toggle="yes">K. pneumoniae</italic>. Comparison between the different conditions tested revealed that 1R6F AqEx produced the most significant zones of inhibition compared with control (PBS) and the other treatments for both <italic toggle="yes">S. pneumoniae</italic> and <italic toggle="yes">K. pneumoniae</italic>. Specifically, the inhibition zones generated by 1R6F AqEx were highly significant (<italic toggle="yes">p</italic> &#x0003c; 0.0001) compared with PBS and significantly larger than those induced by IQOS AqEx (for <italic toggle="yes">S. pneumoniae, p</italic> = 0.002; for <italic toggle="yes">K. pneumonia</italic>, <italic toggle="yes">p</italic> = 0.002). Although clear zones of inhibition were observed for IQOS AqEx in both strains, these did not differ significantly from PBS (<italic toggle="yes">p</italic> &#x0003e; 0.5). Additionally, the inhibition zones produced by 30 &#x000b5;g of CRO were not significantly different from those of either IQOS AqEx or 1R6F AqEx in both strains.</p><p>These results indicate that both IQOS aerosol and 1R6F cigarette smoke demonstrated observable antibacterial activity, with the 1R6F cigarette smoke showing the strongest inhibitory effect across both bacterial strains.</p></sec><sec id="sec3dot1dot2-toxics-13-00070"><title>3.1.2. Bactericidal and Bacteriostatic Effects Against <italic toggle="yes">S. pneumoniae</italic> and <italic toggle="yes">K. pneumoniae</italic></title><p>MIC and MBC values for <italic toggle="yes">S. pneumoniae</italic> and <italic toggle="yes">K. pneumoniae</italic> were reported in <xref rid="toxics-13-00070-t003" ref-type="table">Table 3</xref>. For <italic toggle="yes">S. pneumoniae</italic>, IQOS AqEx demonstrated an MIC of 6.25% <italic toggle="yes">v</italic>/<italic toggle="yes">v</italic> and an MBC of 12.5% <italic toggle="yes">v</italic>/<italic toggle="yes">v</italic>, indicating bacteriostatic effects at lower concentrations and bactericidal effects at slightly higher concentrations. Similarly, the 1R6F AqEx showed both MIC and MBC values of 6.25% <italic toggle="yes">v</italic>/<italic toggle="yes">v</italic>, suggesting that it was effective at inhibiting bacterial growth and reducing bacterial viability at the same concentration.</p><p>For <italic toggle="yes">K. pneumoniae</italic>, IQOS AqEx also demonstrated an MIC of 6.25% <italic toggle="yes">v</italic>/<italic toggle="yes">v</italic> and an MBC of 12.5% <italic toggle="yes">v</italic>/<italic toggle="yes">v</italic>, mirroring the trend observed for <italic toggle="yes">S. pneumoniae</italic>. In contrast, the 1R6F AqEx exhibited both MIC and MBC values of 6.25% <italic toggle="yes">v</italic>/<italic toggle="yes">v</italic>, indicating a more consistent bactericidal effect even at lower concentrations.</p><p>These results further confirm that both IQOS and 1R6F cigarette AqExs possess meaningful antibacterial activity, with 1R6F demonstrating more consistent bactericidal effects across both bacterial strains at lower concentrations.</p></sec></sec><sec id="sec3dot2-toxics-13-00070"><title>3.2. Cell Viability of MRC-5 Against IQOS vs. 1R6F</title><p>The exposure of MRC5 cells to IQOS did not significantly inhibit cell growth, as indicated in <xref rid="toxics-13-00070-f002" ref-type="fig">Figure 2</xref>. This finding suggested that under the tested conditions, IQOS did not exhibit detectable cytotoxic effects on lung fibroblasts. Following air&#x02013;liquid interface (ALI) exposure and a 65 h recovery period, the cells maintained viability comparable to the untreated controls, indicating minimal impact on cell proliferation. In contrast, exposure to 1R6F cigarette smoke caused a pronounced, dose-dependent inhibition of cell growth, with marked cytotoxic effects observed at the highest concentrations tested (4&#x02013;5 cigarettes, <xref rid="toxics-13-00070-f001" ref-type="fig">Figure 1</xref>). This dose&#x02013;response relationship highlighted the significant harmful impact of conventional cigarette smoke on human lung cells, likely due to the higher levels of toxicants and oxidative stress associated with combustion products. Overall, these results demonstrated that, while traditional cigarette smoke exerted a marked cytotoxic effect on lung fibroblasts, the aerosols from IQOS appeared to be considerably less harmful, at least in terms of short-term cell viability.</p></sec><sec id="sec3dot3-toxics-13-00070"><title>3.3. Mutagenicity Assessment</title><p>To validate the Ames assay, several essential criteria were met, including appropriate responses in positive controls (Control Chems: Sodium Azide, Daunomycin, and 2-Aminoanthracene) and negative controls (solvent and air). For a test substance to be considered mutagenic, the following conditions were required: (1) a twofold increase in revertant colonies compared to the negative control (air), (2) a significantly elevated number of revertants at a minimum of three concentrations of the test substance, (3) a positive, linear dose&#x02013;response relationship, and (4) reproducible positive results across independent assays. All criteria for a valid Ames test were successfully met. Negative controls (solvent control) remained within expected ranges based on both laboratory experience and literature values [<xref rid="B29-toxics-13-00070" ref-type="bibr">29</xref>]. Positive controls were within the acceptable range specified by the manufacturer&#x02019;s guidelines (Trinova Biochem GmbH, Gie&#x000df;en, Germany). No significant differences were detected between solvent and air controls (<italic toggle="yes">p</italic> &#x0003e; 0.9) under all conditions. However, significant differences (<italic toggle="yes">p</italic> &#x0003c; 0.0001) were observed between these controls and the Chem controls both in the presence and absence of S9 metabolic activation.</p><p>As reported in <xref rid="toxics-13-00070-f003" ref-type="fig">Figure 3</xref>, a significant (<italic toggle="yes">p</italic> &#x0003c; 0.05) dose-dependent increase in the number of revertants was observed in the TA98 strain following exposure to 1R6F combustible cigarette smoke, with up to five cigarettes used in the assay, indicating a clear mutagenic effect associated with conventional cigarette smoke. Indeed, a number of revertants without S9 metabolic activation showed approximately a 3.0-fold change relative to the air control (<italic toggle="yes">p</italic> &#x0003c; 0.0001). Similarly, when the Ames assay was conducted with S9 metabolic activation, TA98 showed an increase in revertants of nearly 3.0-fold change relative to the air control (<italic toggle="yes">p</italic> &#x0003c; 0.0001) after exposure to 1R6F cigarette smoke. Conversely, exposure to IQOS aerosol did not result in a statistically significant increase in revertants, even at the highest exposure level (up to 30 puffs), compared to the negative control (both with and without S9 metabolic activation). These findings suggest that while traditional cigarette smoke demonstrates mutagenic potential, the IQOS aerosol does not induce comparable mutagenic effects under the tested conditions.</p></sec></sec><sec sec-type="discussion" id="sec4-toxics-13-00070"><title>4. Discussion</title><p>Respiratory infections caused by opportunistic pathogens such as <italic toggle="yes">Klebsiella pneumoniae</italic> and <italic toggle="yes">Streptococcus pneumoniae</italic> pose significant public health challenges, particularly in individuals with chronic conditions like COPD or in healthcare settings where nosocomial infections are prevalent. <italic toggle="yes">K. pneumoniae</italic> is a leading cause of hospital-acquired pneumonia, while <italic toggle="yes">S. pneumoniae</italic> is a common respiratory commensal that can transition to a pathogen under dysbiotic conditions, causing diseases such as pneumonia, sepsis, and meningitis [<xref rid="B30-toxics-13-00070" ref-type="bibr">30</xref>,<xref rid="B31-toxics-13-00070" ref-type="bibr">31</xref>]. Both bacteria are influenced by smoking-induced changes in the respiratory tract, including impaired mucociliary clearance, immune modulation, and altered bacterial adherence [<xref rid="B32-toxics-13-00070" ref-type="bibr">32</xref>,<xref rid="B33-toxics-13-00070" ref-type="bibr">33</xref>].</p><p>Nevertheless, our findings demonstrated differences in the effects of conventional cigarette smoke and THP aerosols on microbial dynamics. In terms of cellular toxicity, cigarette smoke induced a marked and dose-dependent reduction in lung fibroblast viability, reflecting the cytotoxic nature of combusted tobacco smoke. In contrast, exposure to THP aerosols did not reduce fibroblast viability, as cell viability levels remained comparable to those of unexposed controls. This finding highlighted a clear toxicological advantage for THPs, as their aerosols lacked the harmful cellular effects associated with conventional cigarettes [<xref rid="B4-toxics-13-00070" ref-type="bibr">4</xref>,<xref rid="B5-toxics-13-00070" ref-type="bibr">5</xref>]. These results supported their potential role as a harm reduction strategy for individuals unable to quit smoking [<xref rid="B34-toxics-13-00070" ref-type="bibr">34</xref>,<xref rid="B35-toxics-13-00070" ref-type="bibr">35</xref>,<xref rid="B36-toxics-13-00070" ref-type="bibr">36</xref>].</p><p>The mutagenic potential, evaluated via the Ames test, further emphasized the divergence between the two products. Conventional cigarette smoke exhibited a strong mutagenic effect, associated with an elevated carcinogenic risk, whereas THP aerosols showed no detectable mutagenic activity. This suggested that THPs presented a lower long-term risk of carcinogenesis compared to conventional cigarettes [<xref rid="B6-toxics-13-00070" ref-type="bibr">6</xref>,<xref rid="B7-toxics-13-00070" ref-type="bibr">7</xref>].</p><p>However, significant concerns arose regarding the impact of THPs on respiratory microbial communities. We exposed the two bacterial strains to 1R6F AqEx (120 puffs/40 mL) and to IQOS AqEx (120 puffs/40 mL). Both <italic toggle="yes">K. pneumoniae</italic> and <italic toggle="yes">S. pneumoniae</italic> were key members of the respiratory microbiota with dual roles as commensals and opportunistic pathogens. IQOS aerosols demonstrated a bacteriostatic effect on <italic toggle="yes">K. pneumoniae</italic>, potentially disrupting its commensal balance. While the inhibition of bacterial growth might have initially appeared beneficial in reducing pathogenic load, it could destabilize the microbial community and trigger a shift from commensal to pathogenic behavior, increasing the risk of infections [<xref rid="B37-toxics-13-00070" ref-type="bibr">37</xref>,<xref rid="B38-toxics-13-00070" ref-type="bibr">38</xref>,<xref rid="B39-toxics-13-00070" ref-type="bibr">39</xref>]. Similarly, <italic toggle="yes">S. pneumoniae</italic> appeared susceptible to potential disruptions caused by THP aerosols, with implications for respiratory health. Alterations in the balance of this bacterium within the microbiota might have increased susceptibility to pneumococcal diseases, particularly in individuals with underlying conditions or compromised immune systems. These findings underscored the need for further research into the long-term effects of THPs on microbial ecosystems and their implications for respiratory health. Although the number of puffs used to generate AqEx from THPs (120 puffs) and conventional cigarettes (48 puffs) differs, our previous experiments demonstrate that nicotine concentrations in extracts prepared using the same method are comparable: 210 &#x000b5;M for IQOS and 212 &#x000b5;M for 1R6F [<xref rid="B40-toxics-13-00070" ref-type="bibr">40</xref>]. The dose of nicotine delivered thus reflects equivalent exposure for both products. Therefore, the bacteriostatic and bactericidal activity observed in the assays could be primarily attributed to the nicotine present in the extracts, as previously reported in other studies. [<xref rid="B27-toxics-13-00070" ref-type="bibr">27</xref>,<xref rid="B41-toxics-13-00070" ref-type="bibr">41</xref>]. This suggests that substances produced during the combustion process in conventional cigarettes may enhance the bactericidal effects beyond those attributable to nicotine alone.</p><p>This study is one of the few to compare heated tobacco products and cigarettes, focusing on their effects on respiratory microbes and lung cells, with a unique emphasis on bacterial implications. While it highlights reduced toxicity in heated products, it also acknowledges limitations that warrant attention in future research. First, its focus on short-term toxicological effects leaves the long-term impacts of THPs on respiratory health and microbial communities largely unexplored. Additionally, while the study demonstrates potential disruptions to the respiratory microbiota, it does not account for broader ecological shifts or cumulative impacts on microbial homeostasis over time. The use of controlled laboratory conditions and a limited selection of bacterial strains, specifically <italic toggle="yes">Streptococcus pneumoniae</italic> and <italic toggle="yes">Klebsiella pneumoniae</italic>, restricts the generalizability of the findings to real-world situations and the broader respiratory microbiota. Furthermore, reliance on in-vitro models, though informative, does not fully capture in vivo responses or systemic health effects, highlighting the need for comprehensive, long-term investigations.</p></sec><sec sec-type="conclusions" id="sec5-toxics-13-00070"><title>5. Conclusions</title><p>This study highlights a twofold impact of THPs on respiratory health. From a toxicological point of view, THPs showed clear advantages over conventional cigarettes, demonstrating no cytotoxicity or mutagenic potential under the conditions studied. These findings supported the potential of THPs as a harm reduction strategy for smokers unable to quit, offering a less toxic alternative to conventional cigarettes. Conversely, the observed bacteriostatic effects on <italic toggle="yes">K. pneumoniae</italic> and potential disruptions to <italic toggle="yes">S. pneumoniae</italic> have triggered doubts about the impact of THPs on the respiratory microbiota. Alterations in microbial homeostasis could have facilitated the transition of these commensal bacteria to pathogenic states, increasing the risk of respiratory infections and associated complications. In weighing these findings, THPs should be considered a good option for smoking harm reduction, particularly for heavy smokers who are unable or unwilling to quit smoking. However, they were not risk-free and should not have been regarded as a definitive solution to the health risks associated with tobacco use. The potential microbial dysbiosis associated with THPs necessitated cautious evaluation and further investigation to clarify their long-term health implications. Ultimately, while THPs reduced certain risks compared to conventional cigarettes, the broader health implications&#x02014;especially regarding the respiratory microbiota&#x02014;remained uncertain. Any public health recommendations need to balance these factors, emphasizing smoking cessation as the optimal strategy for reducing tobacco-related risks, considering THPs in the context of treatment that leads the smoker to complete smoking cessation.</p></sec></body><back><ack><title>Acknowledgments</title><p>The authors acknowledge Eclat Srl, a research-based spin off company of the University of Catania, for providing the equipment and the materials used in this study.</p></ack><fn-group><fn><p><bold>Disclaimer/Publisher&#x02019;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><notes><title>Author Contributions</title><p>The conceptualization of the study was collaboratively led by P.M.F., V.F. and M.C. The research methodology was designed by V.F. and R.E. The investigation phase was conducted in detail by V.F., S.F. and R.E. The task of data curation was managed by V.F. and R.E. The original draft of the manuscript was prepared by V.F. and S.F. The figures were prepared by V.F. and R.E. The manuscript underwent thorough review and editing by V.F., S.F. and R.E. The overall research process was supervised by P.M.F. and V.F. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Institutional Review Board Statement</title><p>Not applicable.</p></notes><notes><title>Informed Consent Statement</title><p>Not applicable.</p></notes><notes notes-type="data-availability"><title>Data Availability Statement</title><p>All data generated or analyzed during this study are included in this published article.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare that they have no competing interests.</p></notes><glossary><title>List of Abbreviations</title><array><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">ALI</td><td align="left" valign="top" rowspan="1" colspan="1">air&#x02013;liquid interface</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">AqExs</td><td align="left" valign="top" rowspan="1" colspan="1">aqueous extracts</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">BAqEx</td><td align="left" valign="top" rowspan="1" colspan="1">Bacterial aqueous extracts</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">COPD</td><td align="left" valign="top" rowspan="1" colspan="1">chronic obstructive pulmonary disease</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">CRO</td><td align="left" valign="top" rowspan="1" colspan="1">Ceftriaxone</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">MBC</td><td align="left" valign="top" rowspan="1" colspan="1">Minimal bactericidal concentration</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">MIC</td><td align="left" valign="top" rowspan="1" colspan="1">Minimal inhibitory concentration</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">THPs</td><td align="left" valign="top" rowspan="1" colspan="1">tobacco heating products</td></tr></tbody></array></glossary><ref-list><title>References</title><ref id="B1-toxics-13-00070"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bou&#x000e9;</surname><given-names>S.</given-names></name>
<name><surname>Goedertier</surname><given-names>D.</given-names></name>
<name><surname>Hoeng</surname><given-names>J.</given-names></name>
<name><surname>Kuczaj</surname><given-names>A.</given-names></name>
<name><surname>Majeed</surname><given-names>S.</given-names></name>
<name><surname>Mathis</surname><given-names>C.</given-names></name>
<name><surname>May</surname><given-names>A.</given-names></name>
<name><surname>Phillips</surname><given-names>B.</given-names></name>
<name><surname>Peitsch</surname><given-names>M.C.</given-names></name>
<name><surname>Radtke</surname><given-names>F.</given-names></name>
</person-group><article-title>State-of-the-art methods and devices for the generation, exposure, and collection of aerosols from heat-not-burn tobacco products</article-title><source>Toxicol. Res. Appl.</source><year>2020</year><volume>4</volume><fpage>2397847319897869</fpage><pub-id pub-id-type="doi">10.1177/2397847319897869</pub-id></element-citation></ref><ref id="B2-toxics-13-00070"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Emma</surname><given-names>R.</given-names></name>
<name><surname>Caruso</surname><given-names>M.</given-names></name>
<name><surname>Campagna</surname><given-names>D.</given-names></name>
<name><surname>Pulvirenti</surname><given-names>R.</given-names></name>
<name><surname>Li Volti</surname><given-names>G.</given-names></name>
</person-group><article-title>The impact of tobacco cigarettes, vaping products and tobacco heating products on oxidative stress</article-title><source>Antioxidants</source><year>2022</year><volume>11</volume><elocation-id>1829</elocation-id><pub-id pub-id-type="doi">10.3390/antiox11091829</pub-id><pub-id pub-id-type="pmid">36139904</pub-id>
</element-citation></ref><ref id="B3-toxics-13-00070"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Goodall</surname><given-names>S.</given-names></name>
<name><surname>Gale</surname><given-names>N.</given-names></name>
<name><surname>Thorne</surname><given-names>D.</given-names></name>
<name><surname>Hadley</surname><given-names>S.</given-names></name>
<name><surname>Prasad</surname><given-names>K.</given-names></name>
<name><surname>Gilmour</surname><given-names>I.</given-names></name>
<name><surname>Miazzi</surname><given-names>F.</given-names></name>
<name><surname>Proctor</surname><given-names>C.</given-names></name>
</person-group><article-title>Evaluation of behavioural, chemical, toxicological and clinical studies of a tobacco heated product glo&#x02122; and the potential for bridging from a foundational dataset to new product iterations</article-title><source>Toxicol. Rep.</source><year>2022</year><volume>9</volume><fpage>1426</fpage><lpage>1442</lpage><pub-id pub-id-type="doi">10.1016/j.toxrep.2022.06.014</pub-id><pub-id pub-id-type="pmid">36561950</pub-id>
</element-citation></ref><ref id="B4-toxics-13-00070"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kanobe</surname><given-names>M.N.</given-names></name>
<name><surname>Dull</surname><given-names>G.M.</given-names></name>
<name><surname>Darnell</surname><given-names>J.</given-names></name>
<name><surname>Jin</surname><given-names>T.</given-names></name>
<name><surname>Brown</surname><given-names>B.</given-names></name>
<name><surname>Coffield</surname><given-names>J.</given-names></name>
<name><surname>Keyser</surname><given-names>B.M.</given-names></name>
<name><surname>Fearon</surname><given-names>I.M.</given-names></name>
<name><surname>Makena</surname><given-names>P.</given-names></name>
<name><surname>Baxter</surname><given-names>S.A.</given-names></name>
</person-group><article-title>Evaluation of environmental emissions from glo heated tobacco products and combustible Cigarettes</article-title><source>Environ. Adv.</source><year>2024</year><volume>17</volume><fpage>100580</fpage><pub-id pub-id-type="doi">10.1016/j.envadv.2024.100580</pub-id></element-citation></ref><ref id="B5-toxics-13-00070"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gunduz</surname><given-names>I.</given-names></name>
<name><surname>Nordlund</surname><given-names>M.</given-names></name>
<name><surname>King</surname><given-names>J.</given-names></name>
<name><surname>Gustin</surname><given-names>B.</given-names></name>
<name><surname>Cudazzo</surname><given-names>G.</given-names></name>
<name><surname>Nesovic</surname><given-names>M.</given-names></name>
<name><surname>Butin</surname><given-names>Y.</given-names></name>
<name><surname>Stura</surname><given-names>E.</given-names></name>
<name><surname>Alriquet</surname><given-names>M.</given-names></name>
<name><surname>Chauhan</surname><given-names>M.</given-names></name>
</person-group><article-title>A comparative assessment of HPHC yields and in vitro toxicity for 1R6F reference cigarette smoke versus aerosol generated by Tobacco Heating System 3.0</article-title><source>Aerosol Sci. Technol.</source><year>2024</year><volume>59</volume><fpage>146</fpage><lpage>162</lpage><pub-id pub-id-type="doi">10.1080/02786826.2024.2403573</pub-id></element-citation></ref><ref id="B6-toxics-13-00070"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tsolakos</surname><given-names>N.</given-names></name>
<name><surname>Haswell</surname><given-names>L.E.</given-names></name>
<name><surname>Miazzi</surname><given-names>F.</given-names></name>
<name><surname>Bishop</surname><given-names>E.</given-names></name>
<name><surname>Antoranz</surname><given-names>A.</given-names></name>
<name><surname>Pliaka</surname><given-names>V.</given-names></name>
<name><surname>Minia</surname><given-names>A.</given-names></name>
<name><surname>Alexopoulos</surname><given-names>L.G.</given-names></name>
<name><surname>Gaca</surname><given-names>M.</given-names></name>
<name><surname>Breheny</surname><given-names>D.</given-names></name>
</person-group><article-title>Comparative toxicological assessment of cigarettes and new category products via an in vitro multiplex proteomics platform</article-title><source>Toxicol. Rep.</source><year>2024</year><volume>12</volume><fpage>492</fpage><lpage>501</lpage><pub-id pub-id-type="doi">10.1016/j.toxrep.2024.04.006</pub-id><pub-id pub-id-type="pmid">38774478</pub-id>
</element-citation></ref><ref id="B7-toxics-13-00070"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mahlich</surname><given-names>J.</given-names></name>
<name><surname>Kamae</surname><given-names>I.</given-names></name>
</person-group><article-title>Switching from Cigarettes to Heated Tobacco Products in Japan&#x02014;Potential Impact on Health Outcomes and Associated Health Care Costs</article-title><source>Healthcare</source><year>2024</year><volume>12</volume><elocation-id>1937</elocation-id><pub-id pub-id-type="doi">10.3390/healthcare12191937</pub-id><pub-id pub-id-type="pmid">39408118</pub-id>
</element-citation></ref><ref id="B8-toxics-13-00070"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hickman</surname><given-names>E.</given-names></name>
<name><surname>Roca</surname><given-names>C.</given-names></name>
<name><surname>Zorn</surname><given-names>B.T.</given-names></name>
<name><surname>Rebuli</surname><given-names>M.E.</given-names></name>
<name><surname>Robinette</surname><given-names>C.</given-names></name>
<name><surname>Wolfgang</surname><given-names>M.C.</given-names></name>
<name><surname>Jaspers</surname><given-names>I.</given-names></name>
</person-group><article-title>E-Cigarette Use, Cigarette Smoking, and Sex Are Associated With Nasal Microbiome Dysbiosis</article-title><source>Nicotine Tob. Res.</source><year>2024</year><volume>27</volume><fpage>114</fpage><lpage>124</lpage><pub-id pub-id-type="doi">10.1093/ntr/ntae176</pub-id><pub-id pub-id-type="pmid">39018186</pub-id>
</element-citation></ref><ref id="B9-toxics-13-00070"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tattan-Birch</surname><given-names>H.</given-names></name>
<name><surname>Hartmann-Boyce</surname><given-names>J.</given-names></name>
<name><surname>Kock</surname><given-names>L.</given-names></name>
<name><surname>Simonavicius</surname><given-names>E.</given-names></name>
<name><surname>Brose</surname><given-names>L.</given-names></name>
<name><surname>Jackson</surname><given-names>S.</given-names></name>
<name><surname>Shahab</surname><given-names>L.</given-names></name>
<name><surname>Brown</surname><given-names>J.</given-names></name>
</person-group><article-title>Heated tobacco products for smoking cessation and reducing smoking prevalence</article-title><source>Cochrane Database Syst. Rev.</source><year>2022</year><volume>1</volume><fpage>CD013790</fpage><pub-id pub-id-type="pmid">34988969</pub-id>
</element-citation></ref><ref id="B10-toxics-13-00070"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Jankowski</surname><given-names>M.</given-names></name>
<name><surname>Bro&#x0017c;ek</surname><given-names>G.M.</given-names></name>
<name><surname>Lawson</surname><given-names>J.</given-names></name>
<name><surname>Skoczy&#x00144;ski</surname><given-names>S.</given-names></name>
<name><surname>Majek</surname><given-names>P.</given-names></name>
<name><surname>Zejda</surname><given-names>J.E.</given-names></name>
</person-group><article-title>New ideas, old problems? Heated tobacco products&#x02013;a systematic review</article-title><source>Int. J. Occup. Med. Environ. Health</source><year>2019</year><volume>32</volume><fpage>595</fpage><lpage>634</lpage><pub-id pub-id-type="doi">10.13075/ijomeh.1896.01433</pub-id><pub-id pub-id-type="pmid">31584041</pub-id>
</element-citation></ref><ref id="B11-toxics-13-00070"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sawa</surname><given-names>M.</given-names></name>
<name><surname>Ushiyama</surname><given-names>A.</given-names></name>
<name><surname>Inaba</surname><given-names>Y.</given-names></name>
<name><surname>Hattori</surname><given-names>K.</given-names></name>
</person-group><article-title>Increased oxidative stress and effects on inflammatory cytokine secretion by heated tobacco products aerosol exposure to mice</article-title><source>Biochem. Biophys. Res. Commun.</source><year>2022</year><volume>610</volume><fpage>43</fpage><lpage>48</lpage><pub-id pub-id-type="doi">10.1016/j.bbrc.2022.04.042</pub-id><pub-id pub-id-type="pmid">35462100</pub-id>
</element-citation></ref><ref id="B12-toxics-13-00070"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Forster</surname><given-names>M.</given-names></name>
<name><surname>Fiebelkorn</surname><given-names>S.</given-names></name>
<name><surname>Yurteri</surname><given-names>C.</given-names></name>
<name><surname>Mariner</surname><given-names>D.</given-names></name>
<name><surname>Liu</surname><given-names>C.</given-names></name>
<name><surname>Wright</surname><given-names>C.</given-names></name>
<name><surname>McAdam</surname><given-names>K.</given-names></name>
<name><surname>Murphy</surname><given-names>J.</given-names></name>
<name><surname>Proctor</surname><given-names>C.</given-names></name>
</person-group><article-title>Assessment of novel tobacco heating product THP1. 0. Part 3: Comprehensive chemical characterisation of harmful and potentially harmful aerosol emissions</article-title><source>Regul. Toxicol. Pharmacol.</source><year>2018</year><volume>93</volume><fpage>14</fpage><lpage>33</lpage><pub-id pub-id-type="doi">10.1016/j.yrtph.2017.10.006</pub-id><pub-id pub-id-type="pmid">29080848</pub-id>
</element-citation></ref><ref id="B13-toxics-13-00070"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Perez-Cobas</surname><given-names>A.E.</given-names></name>
<name><surname>Rodriguez-Beltran</surname><given-names>J.</given-names></name>
<name><surname>Baquero</surname><given-names>F.</given-names></name>
<name><surname>Coque</surname><given-names>T.M.</given-names></name>
</person-group><article-title>Ecology of the respiratory tract microbiome</article-title><source>Trends Microbiol.</source><year>2023</year><volume>31</volume><fpage>972</fpage><lpage>984</lpage><pub-id pub-id-type="doi">10.1016/j.tim.2023.04.006</pub-id><pub-id pub-id-type="pmid">37173205</pub-id>
</element-citation></ref><ref id="B14-toxics-13-00070"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kitsios</surname><given-names>G.D.</given-names></name>
<name><surname>Nguyen</surname><given-names>V.D.</given-names></name>
<name><surname>Sayed</surname><given-names>K.</given-names></name>
<name><surname>Al-Yousif</surname><given-names>N.</given-names></name>
<name><surname>Schaefer</surname><given-names>C.</given-names></name>
<name><surname>Shah</surname><given-names>F.A.</given-names></name>
<name><surname>Bain</surname><given-names>W.</given-names></name>
<name><surname>Yang</surname><given-names>H.</given-names></name>
<name><surname>Fitch</surname><given-names>A.</given-names></name>
<name><surname>Li</surname><given-names>K.</given-names></name>
<etal/>
</person-group><article-title>The upper and lower respiratory tract microbiome in severe aspiration pneumonia</article-title><source>iScience</source><year>2023</year><volume>26</volume><fpage>106832</fpage><pub-id pub-id-type="doi">10.1016/j.isci.2023.106832</pub-id><pub-id pub-id-type="pmid">37250794</pub-id>
</element-citation></ref><ref id="B15-toxics-13-00070"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhao</surname><given-names>X.</given-names></name>
<name><surname>Hu</surname><given-names>M.</given-names></name>
<name><surname>Zhou</surname><given-names>H.</given-names></name>
<name><surname>Yang</surname><given-names>Y.</given-names></name>
<name><surname>Shen</surname><given-names>S.</given-names></name>
<name><surname>You</surname><given-names>Y.</given-names></name>
<name><surname>Xue</surname><given-names>Z.</given-names></name>
</person-group><article-title>The role of gut microbiome in the complex relationship between respiratory tract infection and asthma</article-title><source>Front. Microbiol.</source><year>2023</year><volume>14</volume><elocation-id>1219942</elocation-id><pub-id pub-id-type="doi">10.3389/fmicb.2023.1219942</pub-id><pub-id pub-id-type="pmid">37577440</pub-id>
</element-citation></ref><ref id="B16-toxics-13-00070"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cicchinelli</surname><given-names>S.</given-names></name>
<name><surname>Rosa</surname><given-names>F.</given-names></name>
<name><surname>Manca</surname><given-names>F.</given-names></name>
<name><surname>Zanza</surname><given-names>C.</given-names></name>
<name><surname>Ojetti</surname><given-names>V.</given-names></name>
<name><surname>Covino</surname><given-names>M.</given-names></name>
<name><surname>Candelli</surname><given-names>M.</given-names></name>
<name><surname>Gasbarrini</surname><given-names>A.</given-names></name>
<name><surname>Franceschi</surname><given-names>F.</given-names></name>
<name><surname>Piccioni</surname><given-names>A.</given-names></name>
</person-group><article-title>The impact of smoking on microbiota: A narrative review</article-title><source>Biomedicines</source><year>2023</year><volume>11</volume><elocation-id>1144</elocation-id><pub-id pub-id-type="doi">10.3390/biomedicines11041144</pub-id><pub-id pub-id-type="pmid">37189762</pub-id>
</element-citation></ref><ref id="B17-toxics-13-00070"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Blasi</surname><given-names>F.</given-names></name>
<name><surname>Mantero</surname><given-names>M.</given-names></name>
<name><surname>Santus</surname><given-names>P.</given-names></name>
<name><surname>Tarsia</surname><given-names>P.</given-names></name>
</person-group><article-title>Understanding the burden of pneumococcal disease in adults</article-title><source>Clin. Microbiol. Infect.</source><year>2012</year><volume>18</volume><issue>(Suppl. S5)</issue><fpage>7</fpage><lpage>14</lpage><pub-id pub-id-type="doi">10.1111/j.1469-0691.2012.03937.x</pub-id><pub-id pub-id-type="pmid">22882668</pub-id>
</element-citation></ref><ref id="B18-toxics-13-00070"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bogaert</surname><given-names>D.</given-names></name>
<name><surname>De Groot</surname><given-names>R.</given-names></name>
<name><surname>Hermans</surname><given-names>P.W.</given-names></name>
</person-group><article-title>Streptococcus pneumoniae colonisation: The key to pneumococcal disease</article-title><source>Lancet Infect. Dis.</source><year>2004</year><volume>4</volume><fpage>144</fpage><lpage>154</lpage><pub-id pub-id-type="doi">10.1016/S1473-3099(04)00938-7</pub-id><pub-id pub-id-type="pmid">14998500</pub-id>
</element-citation></ref><ref id="B19-toxics-13-00070"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Thevaranjan</surname><given-names>N.</given-names></name>
<name><surname>Whelan</surname><given-names>F.J.</given-names></name>
<name><surname>Puchta</surname><given-names>A.</given-names></name>
<name><surname>Ashu</surname><given-names>E.</given-names></name>
<name><surname>Rossi</surname><given-names>L.</given-names></name>
<name><surname>Surette</surname><given-names>M.G.</given-names></name>
<name><surname>Bowdish</surname><given-names>D.M.</given-names></name>
</person-group><article-title>Streptococcus pneumoniae colonization disrupts the microbial community within the upper respiratory tract of aging mice</article-title><source>Infect. Immun.</source><year>2016</year><volume>84</volume><fpage>906</fpage><lpage>916</lpage><pub-id pub-id-type="doi">10.1128/IAI.01275-15</pub-id><pub-id pub-id-type="pmid">26787714</pub-id>
</element-citation></ref><ref id="B20-toxics-13-00070"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Novick</surname><given-names>S.</given-names></name>
<name><surname>Shagan</surname><given-names>M.</given-names></name>
<name><surname>Blau</surname><given-names>K.</given-names></name>
<name><surname>Lifshitz</surname><given-names>S.</given-names></name>
<name><surname>Givon-Lavi</surname><given-names>N.</given-names></name>
<name><surname>Grossman</surname><given-names>N.</given-names></name>
<name><surname>Bodner</surname><given-names>L.</given-names></name>
<name><surname>Dagan</surname><given-names>R.</given-names></name>
<name><surname>Mizrachi Nebenzahl</surname><given-names>Y.</given-names></name>
</person-group><article-title>Adhesion and invasion of Streptococcus pneumoniae to primary and secondary respiratory epithelial cells</article-title><source>Mol. Med. Rep.</source><year>2017</year><volume>15</volume><fpage>65</fpage><lpage>74</lpage><pub-id pub-id-type="doi">10.3892/mmr.2016.5996</pub-id><pub-id pub-id-type="pmid">27922699</pub-id>
</element-citation></ref><ref id="B21-toxics-13-00070"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Podschun</surname><given-names>R.</given-names></name>
<name><surname>Ullmann</surname><given-names>U.</given-names></name>
</person-group><article-title><italic toggle="yes">Klebsiella</italic> spp. as nosocomial pathogens: Epidemiology, taxonomy, typing methods, and pathogenicity factors</article-title><source>Clin. Microbiol. Rev.</source><year>1998</year><volume>11</volume><fpage>589</fpage><lpage>603</lpage><pub-id pub-id-type="doi">10.1128/CMR.11.4.589</pub-id><pub-id pub-id-type="pmid">9767057</pub-id>
</element-citation></ref><ref id="B22-toxics-13-00070"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Piperaki</surname><given-names>E.T.</given-names></name>
<name><surname>Syrogiannopoulos</surname><given-names>G.A.</given-names></name>
<name><surname>Tzouvelekis</surname><given-names>L.S.</given-names></name>
<name><surname>Daikos</surname><given-names>G.L.</given-names></name>
</person-group><article-title>Klebsiella pneumoniae: Virulence, Biofilm and Antimicrobial Resistance</article-title><source>Pediatr. Infect. Dis. J.</source><year>2017</year><volume>36</volume><fpage>1002</fpage><lpage>1005</lpage><pub-id pub-id-type="doi">10.1097/INF.0000000000001675</pub-id><pub-id pub-id-type="pmid">28914748</pub-id>
</element-citation></ref><ref id="B23-toxics-13-00070"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sharan</surname><given-names>H.</given-names></name>
</person-group><article-title>Aerobic Bacteriological Study of Acute Exacerbations of Chronic Obstructive Pulmonary Disease</article-title><source>J. Clin. Diagn. Res.</source><year>2015</year><volume>9</volume><fpage>DC10</fpage><lpage>DC12</lpage><pub-id pub-id-type="doi">10.7860/JCDR/2015/14515.6367</pub-id><pub-id pub-id-type="pmid">26435942</pub-id>
</element-citation></ref><ref id="B24-toxics-13-00070"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Budisan</surname><given-names>L.</given-names></name>
<name><surname>Zanoaga</surname><given-names>O.</given-names></name>
<name><surname>Braicu</surname><given-names>C.</given-names></name>
<name><surname>Pirlog</surname><given-names>R.</given-names></name>
<name><surname>Covaliu</surname><given-names>B.</given-names></name>
<name><surname>Esanu</surname><given-names>V.</given-names></name>
<name><surname>Korban</surname><given-names>S.S.</given-names></name>
<name><surname>Berindan-Neagoe</surname><given-names>I.</given-names></name>
</person-group><article-title>Links between Infections, Lung Cancer, and the Immune System</article-title><source>Int. J. Mol. Sci.</source><year>2021</year><volume>22</volume><elocation-id>9394</elocation-id><pub-id pub-id-type="doi">10.3390/ijms22179394</pub-id><pub-id pub-id-type="pmid">34502312</pub-id>
</element-citation></ref><ref id="B25-toxics-13-00070"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Shen</surname><given-names>P.</given-names></name>
<name><surname>Morissette</surname><given-names>M.C.</given-names></name>
<name><surname>Vanderstocken</surname><given-names>G.</given-names></name>
<name><surname>Gao</surname><given-names>Y.</given-names></name>
<name><surname>Hassan</surname><given-names>M.</given-names></name>
<name><surname>Roos</surname><given-names>A.</given-names></name>
<name><surname>Thayaparan</surname><given-names>D.</given-names></name>
<name><surname>Merlano</surname><given-names>M.</given-names></name>
<name><surname>Dorrington</surname><given-names>M.G.</given-names></name>
<name><surname>Nikota</surname><given-names>J.K.</given-names></name>
<etal/>
</person-group><article-title>Cigarette Smoke Attenuates the Nasal Host Response to Streptococcus pneumoniae and Predisposes to Invasive Pneumococcal Disease in Mice</article-title><source>Infect. Immun.</source><year>2016</year><volume>84</volume><fpage>1536</fpage><lpage>1547</lpage><pub-id pub-id-type="doi">10.1128/IAI.01504-15</pub-id><pub-id pub-id-type="pmid">26930709</pub-id>
</element-citation></ref><ref id="B26-toxics-13-00070"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mallock</surname><given-names>N.</given-names></name>
<name><surname>Pieper</surname><given-names>E.</given-names></name>
<name><surname>Hutzler</surname><given-names>C.</given-names></name>
<name><surname>Henkler-Stephani</surname><given-names>F.</given-names></name>
<name><surname>Luch</surname><given-names>A.</given-names></name>
</person-group><article-title>Heated tobacco products: A review of current knowledge and initial assessments</article-title><source>Front. Public Health</source><year>2019</year><volume>7</volume><elocation-id>287</elocation-id><pub-id pub-id-type="doi">10.3389/fpubh.2019.00287</pub-id><pub-id pub-id-type="pmid">31649912</pub-id>
</element-citation></ref><ref id="B27-toxics-13-00070"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Fuochi</surname><given-names>V.</given-names></name>
<name><surname>Caruso</surname><given-names>M.</given-names></name>
<name><surname>Emma</surname><given-names>R.</given-names></name>
<name><surname>Stivala</surname><given-names>A.</given-names></name>
<name><surname>Polosa</surname><given-names>R.</given-names></name>
<name><surname>Distefano</surname><given-names>A.</given-names></name>
<name><surname>Furneri</surname><given-names>P.M.</given-names></name>
</person-group><article-title>Investigation on the antibacterial activity of electronic cigarette liquids (ECLs): A proof of concept study</article-title><source>Curr. Pharm. Biotechnol.</source><year>2020</year><volume>22</volume><fpage>983</fpage><lpage>994</lpage><pub-id pub-id-type="doi">10.2174/1389201021666200903121624</pub-id><pub-id pub-id-type="pmid">32881666</pub-id>
</element-citation></ref><ref id="B28-toxics-13-00070"><label>28.</label><element-citation publication-type="book"><person-group person-group-type="author">
<collab>CLSI</collab>
</person-group><source>M100: Performance Standards for Antimicrobial Susceptibility Testing</source><edition>32nd ed.</edition><publisher-name>Clinical Laboratory Standards Institute</publisher-name><publisher-loc>Wayne, PA, USA</publisher-loc><year>2022</year></element-citation></ref><ref id="B29-toxics-13-00070"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Emma</surname><given-names>R.</given-names></name>
<name><surname>Fuochi</surname><given-names>V.</given-names></name>
<name><surname>Distefano</surname><given-names>A.</given-names></name>
<name><surname>Partsinevelos</surname><given-names>K.</given-names></name>
<name><surname>Rust</surname><given-names>S.</given-names></name>
<name><surname>Zadjali</surname><given-names>F.</given-names></name>
<name><surname>Al Tobi</surname><given-names>M.</given-names></name>
<name><surname>Zadjali</surname><given-names>R.</given-names></name>
<name><surname>Alharthi</surname><given-names>Z.</given-names></name>
<name><surname>Pulvirenti</surname><given-names>R.</given-names></name>
<etal/>
</person-group><article-title>Cytotoxicity, mutagenicity and genotoxicity of electronic cigarettes emission aerosols compared to cigarette smoke: The REPLICA project</article-title><source>Sci. Rep.</source><year>2024</year><volume>14</volume><elocation-id>10018</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-024-53036-w</pub-id><pub-id pub-id-type="pmid">38693204</pub-id>
</element-citation></ref><ref id="B30-toxics-13-00070"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chen</surname><given-names>I.-R.</given-names></name>
<name><surname>Lin</surname><given-names>S.-N.</given-names></name>
<name><surname>Wu</surname><given-names>X.-N.</given-names></name>
<name><surname>Chou</surname><given-names>S.-H.</given-names></name>
<name><surname>Wang</surname><given-names>F.-D.</given-names></name>
<name><surname>Lin</surname><given-names>Y.-T.</given-names></name>
</person-group><article-title>Clinical and microbiological characteristics of bacteremic pneumonia caused by Klebsiella pneumoniae</article-title><source>Front. Cell. Infect. Microbiol.</source><year>2022</year><volume>12</volume><elocation-id>903682</elocation-id><pub-id pub-id-type="doi">10.3389/fcimb.2022.903682</pub-id><pub-id pub-id-type="pmid">35811668</pub-id>
</element-citation></ref><ref id="B31-toxics-13-00070"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hakansson</surname><given-names>A.</given-names></name>
<name><surname>Orihuela</surname><given-names>C.</given-names></name>
<name><surname>Bogaert</surname><given-names>D.</given-names></name>
</person-group><article-title>Bacterial-host interactions: Physiology and pathophysiology of respiratory infection</article-title><source>Physiol. Rev.</source><year>2018</year><volume>98</volume><fpage>781</fpage><lpage>811</lpage><pub-id pub-id-type="doi">10.1152/physrev.00040.2016</pub-id><pub-id pub-id-type="pmid">29488821</pub-id>
</element-citation></ref><ref id="B32-toxics-13-00070"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>O&#x02019;Brien</surname><given-names>W.J.</given-names></name>
<name><surname>Gupta</surname><given-names>K.</given-names></name>
<name><surname>Itani</surname><given-names>K.M.F.</given-names></name>
</person-group><article-title>Association of Postoperative Infection with Risk of Long-term Infection and Mortality</article-title><source>JAMA Surg.</source><year>2020</year><volume>155</volume><fpage>61</fpage><lpage>68</lpage><pub-id pub-id-type="doi">10.1001/jamasurg.2019.4539</pub-id><pub-id pub-id-type="pmid">31693076</pub-id>
</element-citation></ref><ref id="B33-toxics-13-00070"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Itani</surname><given-names>R.</given-names></name>
<name><surname>Khojah</surname><given-names>H.M.J.</given-names></name>
<name><surname>Kibrit</surname><given-names>R.</given-names></name>
<name><surname>Raychouni</surname><given-names>H.</given-names></name>
<name><surname>Shuhaiber</surname><given-names>P.</given-names></name>
<name><surname>Dib</surname><given-names>C.</given-names></name>
<name><surname>Hassan</surname><given-names>M.</given-names></name>
<name><surname>Mukattash</surname><given-names>T.L.</given-names></name>
<name><surname>El-Lakany</surname><given-names>A.</given-names></name>
</person-group><article-title>Risk factors associated with multidrug-resistant Klebsiella pneumoniae infections: A multicenter observational study in Lebanese hospitals</article-title><source>BMC Public Health</source><year>2024</year><volume>24</volume><elocation-id>2958</elocation-id><pub-id pub-id-type="doi">10.1186/s12889-024-20474-0</pub-id><pub-id pub-id-type="pmid">39449026</pub-id>
</element-citation></ref><ref id="B34-toxics-13-00070"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bravo-Gutierrez</surname><given-names>O.A.</given-names></name>
<name><surname>Falfan-Valencia</surname><given-names>R.</given-names></name>
<name><surname>Ramirez-Venegas</surname><given-names>A.</given-names></name>
<name><surname>Sansores</surname><given-names>R.H.</given-names></name>
<name><surname>Ponciano-Rodriguez</surname><given-names>G.</given-names></name>
<name><surname>Perez-Rubio</surname><given-names>G.</given-names></name>
</person-group><article-title>Lung Damage Caused by Heated Tobacco Products and Electronic Nicotine Delivery Systems: A Systematic Review</article-title><source>Int. J. Environ. Res. Public Health</source><year>2021</year><volume>18</volume><elocation-id>4079</elocation-id><pub-id pub-id-type="doi">10.3390/ijerph18084079</pub-id><pub-id pub-id-type="pmid">33924379</pub-id>
</element-citation></ref><ref id="B35-toxics-13-00070"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Polosa</surname><given-names>R.</given-names></name>
<name><surname>Morjaria</surname><given-names>J.B.</given-names></name>
<name><surname>Prosperini</surname><given-names>U.</given-names></name>
<name><surname>Busa</surname><given-names>B.</given-names></name>
<name><surname>Pennisi</surname><given-names>A.</given-names></name>
<name><surname>Gussoni</surname><given-names>G.</given-names></name>
<name><surname>Rust</surname><given-names>S.</given-names></name>
<name><surname>Maglia</surname><given-names>M.</given-names></name>
<name><surname>Caponnetto</surname><given-names>P.</given-names></name>
</person-group><article-title>Health outcomes in COPD smokers using heated tobacco products: A 3-year follow-up</article-title><source>Intern. Emerg. Med.</source><year>2021</year><volume>16</volume><fpage>687</fpage><lpage>696</lpage><pub-id pub-id-type="doi">10.1007/s11739-021-02674-3</pub-id><pub-id pub-id-type="pmid">33754228</pub-id>
</element-citation></ref><ref id="B36-toxics-13-00070"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tsou</surname><given-names>H.H.</given-names></name>
<name><surname>Wang</surname><given-names>P.H.</given-names></name>
<name><surname>Ting</surname><given-names>T.H.</given-names></name>
<name><surname>Ping</surname><given-names>Y.H.</given-names></name>
<name><surname>Liu</surname><given-names>T.Y.</given-names></name>
<name><surname>Cheng</surname><given-names>H.W.</given-names></name>
<name><surname>Wang</surname><given-names>H.T.</given-names></name>
</person-group><article-title>Effect of heated tobacco products and traditional cigarettes on pulmonary toxicity and SARS-CoV-2-induced lung injury</article-title><source>Toxicology</source><year>2022</year><volume>479</volume><fpage>153318</fpage><pub-id pub-id-type="doi">10.1016/j.tox.2022.153318</pub-id><pub-id pub-id-type="pmid">36096319</pub-id>
</element-citation></ref><ref id="B37-toxics-13-00070"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Casadevall</surname><given-names>A.</given-names></name>
<name><surname>Pirofski</surname><given-names>L.A.</given-names></name>
</person-group><article-title>Host-pathogen interactions: Basic concepts of microbial commensalism, colonization, infection, and disease</article-title><source>Infect. Immun.</source><year>2000</year><volume>68</volume><fpage>6511</fpage><lpage>6518</lpage><pub-id pub-id-type="doi">10.1128/IAI.68.12.6511-6518.2000</pub-id><pub-id pub-id-type="pmid">11083759</pub-id>
</element-citation></ref><ref id="B38-toxics-13-00070"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Barber</surname><given-names>M.F.</given-names></name>
<name><surname>Fitzgerald</surname><given-names>J.R.</given-names></name>
</person-group><article-title>Mechanisms of host adaptation by bacterial pathogens</article-title><source>FEMS Microbiol. Rev.</source><year>2024</year><volume>48</volume><elocation-id>fuae019</elocation-id><pub-id pub-id-type="doi">10.1093/femsre/fuae019</pub-id><pub-id pub-id-type="pmid">39003250</pub-id>
</element-citation></ref><ref id="B39-toxics-13-00070"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Brugger</surname><given-names>S.D.</given-names></name>
<name><surname>Bomar</surname><given-names>L.</given-names></name>
<name><surname>Lemon</surname><given-names>K.P.</given-names></name>
</person-group><article-title>Commensal-Pathogen Interactions along the Human Nasal Passages</article-title><source>PLoS Pathog.</source><year>2016</year><volume>12</volume><elocation-id>e1005633</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1005633</pub-id><pub-id pub-id-type="pmid">27389401</pub-id>
</element-citation></ref><ref id="B40-toxics-13-00070"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Distefano</surname><given-names>A.</given-names></name>
<name><surname>Orlando</surname><given-names>L.</given-names></name>
<name><surname>Partsinevelos</surname><given-names>K.</given-names></name>
<name><surname>Longhitano</surname><given-names>L.</given-names></name>
<name><surname>Emma</surname><given-names>R.</given-names></name>
<name><surname>Caruso</surname><given-names>M.</given-names></name>
<name><surname>Vicario</surname><given-names>N.</given-names></name>
<name><surname>Denaro</surname><given-names>S.</given-names></name>
<name><surname>Sun</surname><given-names>A.</given-names></name>
<name><surname>Giordano</surname><given-names>A.</given-names></name>
<etal/>
</person-group><article-title>Comparative evaluation of cigarette smoke and a heated tobacco product on microglial toxicity, oxidative stress and inflammatory response</article-title><source>J. Transl. Med.</source><year>2024</year><volume>22</volume><fpage>876</fpage><pub-id pub-id-type="doi">10.1186/s12967-024-05688-5</pub-id><pub-id pub-id-type="pmid">39350202</pub-id>
</element-citation></ref><ref id="B41-toxics-13-00070"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Pavia</surname><given-names>C.S.</given-names></name>
<name><surname>Plummer</surname><given-names>M.M.</given-names></name>
</person-group><article-title>Clinical implications of nicotine as an antimicrobial agent and immune modulator</article-title><source>Biomed. Pharmacother.</source><year>2020</year><volume>129</volume><elocation-id>110404</elocation-id><pub-id pub-id-type="doi">10.1016/j.biopha.2020.110404</pub-id><pub-id pub-id-type="pmid">32603888</pub-id>
</element-citation></ref></ref-list></back><floats-group><fig position="float" id="toxics-13-00070-f001"><label>Figure 1</label><caption><p>Barplot illustrating inhibition zones measured in the agar diffusion test for (<bold>A</bold>) <italic toggle="yes">S. pneumoniae</italic> and (<bold>B</bold>) <italic toggle="yes">K. pneumoniae</italic>, respectively. Data are reported as means + SD. Statistical significance was indicated as ** <italic toggle="yes">p</italic> &#x0003c; 0.01, **** <italic toggle="yes">p</italic> &#x0003c; 0.0001.</p></caption><graphic xlink:href="toxics-13-00070-g001" position="float"/></fig><fig position="float" id="toxics-13-00070-f002"><label>Figure 2</label><caption><p>Barplot illustrating MRC-5 cell viability following exposure to THP aerosol (up to 36 puffs) and 1R6F smoke (up to 5 cigarettes). Data are expressed as percentage of the respective air control and displayed as means &#x000b1; SD, based on 9 replicate wells from triplicate transwell experiments. Statistical significance was indicated as ** <italic toggle="yes">p</italic> &#x0003c; 0.01, **** <italic toggle="yes">p</italic> &#x0003c; 0.0001.</p></caption><graphic xlink:href="toxics-13-00070-g002" position="float"/></fig><fig position="float" id="toxics-13-00070-f003"><label>Figure 3</label><caption><p>Mutagenicity assessment using the Ames test was conducted on S. typhimurium TA98 without (<bold>A</bold>) and with (<bold>B</bold>) S9 metabolic activation following exposure to 1R6F combustible cigarette smoke (red lines) or IQOS (blue lines). Results were expressed as fold change relative to the air control. The means &#x000b1; SD of revertant colonies in solvent controls for TA98 during 1R6F experiments were 20.20 &#x000b1; 2.56 (S9&#x02212;) and 29.8 &#x000b1; 13.72 (S9+), whereas for IQOS experiments, they were 5.53 &#x000b1; 1.95 (S9&#x02212;) and 6.46 &#x000b1; 1.59 (S9+). Each data point represents the mean &#x000b1; SD from triplicate Petri dishes. Dashed lines indicate the 95% confidence interval of the regression line.</p></caption><graphic xlink:href="toxics-13-00070-g003" position="float"/></fig><table-wrap position="float" id="toxics-13-00070-t001"><object-id pub-id-type="pii">toxics-13-00070-t001_Table 1</object-id><label>Table 1</label><caption><p>Schematic representation of the assay. The example is intended for both S9&#x02212; and S9+ mix in 2 mL of melted top-agar for tube.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">Assay Mix</th><th colspan="4" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">Components to Add into Melted Agar</th></tr><tr><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">BAqEx *</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Air Control</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Solvent Control</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Control Chem</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">S9&#x02212;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">200 &#x003bc;L of BAqEx</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">200 &#x003bc;L of BAqEx air control</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">100 &#x003bc;L of PBS + 100 &#x003bc;L of the untreated PBS bacterial suspension</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">100 &#x003bc;L of controlchem solution + 100 &#x003bc;L of untreated PBS bacterial suspension</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">S9+</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">500 &#x003bc;L S9+ mix and 50 &#x003bc;L of BAqEx</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">500 &#x003bc;L S9+ mix and 50 &#x003bc;L of BAqEx air control</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">500 &#x003bc;L S9+ mix + 50 &#x003bc;L of the untreated PBS bacterial suspension</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">500 &#x003bc;L S9+ mix + 100 &#x003bc;L of controlchem solution + 50 &#x003bc;L of the untreated PBS bacterial suspension</td></tr></tbody></table><table-wrap-foot><fn><p>* Bacterial aqueous extracts.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="toxics-13-00070-t002"><object-id pub-id-type="pii">toxics-13-00070-t002_Table 2</object-id><label>Table 2</label><caption><p>Zones of inhibition measured in mm (diameter) caused by the aqueous extracts (AqExs).</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Strain</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">IQOS AqEx</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">1R6F AqEx</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">PBS</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">CRO 30 &#x000b5;g</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">p</italic> Value</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">S. pneumoniae</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">22 &#x000b1; 0.2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">29 &#x000b1; 0.2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02264;6 *</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">26 &#x000b1; 0.1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">K. pneumoniae</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">21 &#x000b1; 0.1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">27 &#x000b1; 0.3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02264;6 *</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">23 &#x000b1; 0.2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003c;0.0001</td></tr></tbody></table><table-wrap-foot><fn><p>Data are presented as mean &#x000b1; SD; * &#x02264;6: no susceptibility.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="toxics-13-00070-t003"><object-id pub-id-type="pii">toxics-13-00070-t003_Table 3</object-id><label>Table 3</label><caption><p>MIC and MBC values of AqExs expressed as % <italic toggle="yes">v</italic>/<italic toggle="yes">v</italic>.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">Strain</th><th colspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">IQOS AqEx *</th><th colspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">1R6F AqEx *</th></tr><tr><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MIC</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MBC</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MIC</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MBC</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">S. pneumoniae</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6.25</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">12.5</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6.25</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6.25</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">K. pneumoniae</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6.25</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">12.5</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6.25</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6.25</td></tr></tbody></table><table-wrap-foot><fn><p>* AqEx: aqueous extract.</p></fn></table-wrap-foot></table-wrap></floats-group></article>